Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Abstract Background Pricing and reimbursement decisions for orphan drugs are faced with differences access between European countries depending on each reimbursement policies, evaluation processes and timings. In 2013, the therapeutic positioning report was introduced in the pricing and reimbursemen...
Main Authors: | Xavier Badia, Tania Vico, John Shepherd, Alicia Gil, José Luis Poveda-Andrés, César Hernández |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-020-01507-4 |
Similar Items
-
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
by: José Luis Poveda, et al.
Published: (2023-01-01) -
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01) -
A systematic review of moral reasons on orphan drug reimbursement
by: Bettina M. Zimmermann, et al.
Published: (2021-06-01) -
Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01) -
Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper
by: N. Zozaya, et al.
Published: (2023-02-01)